Compare Stryker Corporation (SYK) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Stryker Corporation trades at $277.29 (market cap $106.24B), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.28 (market cap $27.10B). The key difference: Stryker Corporation is far larger — about 3.9× Vanguard S&P 500 Growth Index Fund ETF's market cap, and Stryker Corporation pays a 1.27% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Vanguard S&P 500 Growth Index Fund ETF for 54 Days on average.
| SYK | VOOG | |
|---|---|---|
Market Cap | $106.24B | $27.10B |
Volume | 2,982,001 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $388.35 | $87.81 |
52-Week Low | $269.75 | $65.32 |
Typical Hold Time | 21 Days | 54 Days |
Enterprise Value | $117.70B | — |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
VOOG trades at $87.69, down slightly by 0.14% on the day, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including an overbought RSI. The ETF, tracking the S&P 500 Growth Index, has delivered strong long-term returns, with recent news highlighting institutional buying and outperformance versus peers. Key support sits at $87, resistance at $88.
Outlook remains positive for long-term growth investors given VOOG's low expense ratio and historical outperformance, though near-term risks include tech sector concentration and market volatility. The ETF's focus on large-cap growth stocks positions it well for sustained appreciation, but investors should be cautious of valuation extremes in growth segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
